Insights - Page 40 of 107 - LucidQuest Ventures

Oncology Video Recap—November 24, 2025

November 24, 2025BetaGlue Therapeutics,ITM Isotope Technologies Munich,bayer,Hamlet BioPharma,merck,msd,breast cancer,BioPharma and Tech News,Pancreatic cancer,bladder cancer,Regeneron,neuroendocrine tumors,Oncology News,Non-small cell lung cancer,Cutaneous squamous cell carcinomaAvenzo Therapeutics,Celcuity

Explore our biweekly Oncology video recap to learn about Fast Track and…

by LucidQuest

Oncology Today—November 24, 2025

November 24, 2025Amgen,merck,breast cancer,BioPharma and Tech News,Colorectal Cancer,Pancreatic cancer,gastric cancer,Keytruda,Libtayo,Small Cell Lung CancerOncology News,Non-small cell lung cancer

This week’s oncology update spotlights key developments, regulatory milestones,…

by LucidQuest

AI in Healthcare and Digital Health Today—November 24, 2025

November 24, 2025BioPharma and Tech News,type 2 diabetesAtrial fibrillation,Long COVID,AI in Healthcare and Digital Health,chronic obstructive pulmonary disease,Pediatric obesity

This week's AI in Healthcare and Digital Health update highlights…

by Timos Papagatsias

Lucid Diligence Brief: Aspen Neuroscience $115M Series C

November 24, 2025venture capital,clinical trials,Regulatory,Cell Therapy,Parkinson's Disease,biopharma,iPSC,Lucid Diligence Brief,payer access,diligencemanufacturing

Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…

by Timos Papagatsias

Lucid Diligence Brief: Function Health raises $298M Series B at $2.5B

November 23, 2025digital health,Regulatory,AI in healthcare,biopharma,Lucid Diligence Brief,payer access,venture funding,radiology,diagnostic imaging,clinical utilitypreventive health

Lucid Diligence Brief: Function Health raises $298M Series B at $2.5B…

by Timos Papagatsias

Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home Alzheimer’s blood collection

November 22, 2025digital health,clinical trials,market access,Regulatory,Alzheimers,biopharma,medtech,diagnostics,Lucid Diligence Brief,payer access,diligencehome collection

Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home…

by Timos Papagatsias

Lucid Diligence Brief: WellBeam $10M Series A

November 21, 2025digital health,market access,reimbursement,Lucid Diligence Brief,payer access,diligence,clinical workflows,biopharma adjacency,interoperability,TEFCA,care coordinationhealth IT

Lucid Diligence Brief: WellBeam $10M Series A Professional audiences only. Not…

by Timos Papagatsias

Public Health Video Recap—November 21, 2025

November 21, 2025CRISPR Cas9,Sorfequiline,novartis,BioPharma and Tech News,tuberculosis,Vitamin D,Cleveland Clinic,Public Health News,TB Alliance,NYU Langone Health,GanLum,AHA Scientific Sessions,The Lancet,Microplastic exposureGanaplacide,Lumefantrine

This week’s Public Health news brings you late-stage trial wins, early…

by LucidQuest

Public Health Today—21 November, 2025

November 21, 2025BioPharma and Tech News,tuberculosisTirzepatide,Eli Lilly,Atrial fibrillation,Long COVID,Ultra-processed foods,smoking cessation,Public Health News,Menopause hormone therapy,chronic disease,knee osteoarthritis

Discover what’s new in public health this week—including industry updates,…

by LucidQuest

Respiratory Today—November 21, 2025

November 21, 2025cystic fibrosis,COPD,Asthma,BioPharma and Tech News,Bronchiectasis,tuberculosis,Vast Therapeutics,Respiratory News,cipla,Insmed,Windtree Therapeutics,ReCode TherapeuticsTB Alliance,Neonatal respiratory distress syndrome

Discover what’s new in Respiratory this week including regulatory approvals,…

by LucidQuest

Vaccines Today—November 21, 2025

November 21, 2025multiple sclerosis,gsk,pfizer,breast cancer,Moderna,BioPharma and Tech News,Small Cell Lung Cancer,Vaccine news,influenza,Duke Health,Cancer Research UK,MFDS Korearespiratory syncytial virus,Epstein Barr virus

Stay updated with this week’s Vaccines insights covering early immunotherapy…

by LucidQuest

Lucid Diligence Brief: Abbott to acquire Exact Sciences

November 21, 2025clinical trials,market access,reimbursement,Regulatory,precision oncology,biopharma,Cancer Screening,diagnostics,Lucid Diligence Brief,payer access,diligenceM&A

Lucid Diligence Brief: Abbott to acquire Exact Sciences Professional audiences…

by Timos Papagatsias

Minimize Uncertainty – Make Informed Decisions – Succeed